Sydney, Australia (CU)_ Telix Pharmaceuticals Limited revealed that it has signed a commercial distribution agreement with Global Medical Solutions Australia (GMSA) for the prostate cancer imaging product of Telix known as Illuccix®, which is a Kit for the preparation of 68Ga-PSMA-11, in the Australian market. GMSA is an international manufacturer and marketer of diagnostic and therapeutic radiopharmaceuticals with 16 radiopharmacies located around the Asia Pacific region.
The distribution arrangement dramatically increases patient access to Illuccix, which will now be offered to every PET/CT1 facility in Australia via GSMA, which will supply Illuccix kits and 68Ga-PSMA-11 unit doses through its network of six radiopharmacies around the nation. The agreement’s initial duration is five years. The deal is subject to commercial performance and termination terms consistent with industry standards.
Having acquired marketing clearance from the Australian Therapeutic Goods Administration (TGA) in November 2021, Illuccix became Australia’s first regulatory-approved PET agent for prostate cancer diagnostic imaging. Australia has one of the world’s highest prostate cancer rates. Prostate cancer was the most often diagnosed cancer among males in Australia in 2020, accounting for roughly 18,000 new cases.
Dr. David Cade, CEO of Telix Asia Pacific, expressed optimism about the partnership with GMSA. He said, “We are pleased to have entered this commercial distribution agreement with GMSA, thus delivering a key component of Telix’s supply chain strategy in Australia, our home market. This builds on the clinical supply agreement signed in April last year, which has enabled the manufacturing and supply of finished unit doses for Telix’s CUPID3 and ProstACT4 studies of TLX592 and TLX591, respectively. GMSA has built an extensive nuclear pharmacy distribution network in Australia, through which we will deliver broad equity of access to state-of-the-art imaging for all Australian men living with prostate cancer. This includes men living in regional and rural Australia, where access to advanced prostate cancer imaging has traditionally been poor.”
Shahe Bagerdjian, Senior Vice President of Operations and Business Development at GMSA, expressed delight over the collaboration with Telix. He said, “We are delighted to be expanding our partnership with Telix and we look forward to bringing Illuccix® and patient-specific 68Ga-PSMA-11 unit doses to Australian men in need through our market-leading radiopharmacy network. This commercial partnership with Telix opens the door to the new standard of care in prostate cancer imaging for the 18,000 men diagnosed with prostate cancer each year in Australia.”
